Prima applies for IND
Tuesday, 28 April, 2009
Sydney’s Prima BioMed has begun the application process for an investigational new drug with the US FDA for its CVac ovarian cancer adjuvant vaccine.
The Sydney company has also raised an extra $1.5 million from a significant new investor, on top of the $12 million funding facility it secured from investment back Fortrend Securities in March.
Prima is also offering a share purchase plan for existing shareholders to help fund its upcoming pivotal trial.
The company is treating one patient in Australia under the TGA’s special access scheme and has progressed through early stage trials.
CVac is a vaccine administered after surgery and chemotherapy to delay relapse and control metastases. It consists of a mannan fusion protein to target mucin 1 on cancer cells, which stimulates the immune system to attack the tumour.
Quitting smoking increases life expectancy even for seniors
Although the benefits of quitting smoking diminish with age, there are still substantial gains...
Stem cell transplants treat blindness in mini pigs
Scientists have successfully transplanted retinas made from stem cells into blind mini pigs,...
Sugary drinks raise cardiovascular disease risk, but occasional sweets don't
Although higher sugar intake raises your risk of certain cardiovascular diseases, consuming sweet...
